KK-LC-1 TCR-T cells for Stomach Cancer

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Stomach Cancer+3 More ConditionsKK-LC-1 TCR-T cells - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer treatment involving TCR-T cells. Participants will receive infusions of the cells, as well as aldesleukin, and doctors will monitor for safety and effectiveness.

Eligible Conditions
  • Stomach Cancer
  • Cervical Cancer
  • Breast Cancer
  • Lung Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Through study completion, up to 5 years

30 days
Adverse events of KK-LC-1 TCR T cells
T-Cell Receptor
6 weeks
Tumor response rate
Year 5
Tumor response duration

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

KK-LC-1 TCR-T cells
1 of 1

Experimental Treatment

42 Total Participants · 1 Treatment Group

Primary Treatment: KK-LC-1 TCR-T cells · No Placebo Group · Phase 1

KK-LC-1 TCR-T cellsExperimental Group · 2 Interventions: KK-LC-1 TCR-T cells, Aldesleukin 720,000 IU/kg IV every eight hours · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 5 years

Who is running the clinical trial?

Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New JerseyUNKNOWN
Christian HinrichsLead Sponsor
2 Previous Clinical Trials
35 Total Patients Enrolled
T Cure BioscienceUNKNOWN
National Cancer Institute (NCI)NIH
13,273 Previous Clinical Trials
41,234,677 Total Patients Enrolled
Christian S Hinrichs, MDPrincipal InvestigatorRutgers Cancer Institute of New Jersey
1 Previous Clinical Trials
15 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can participate if you have three or fewer brain tumors that have been treated with surgery or targeted radiation therapy. If your tumors were treated with targeted radiation therapy, they must not have changed in size for at least one month before starting the trial. If you had surgery to remove a brain tumor, you are eligible to participate.

Frequently Asked Questions

Has the FDA sanctioned KK-LC-1 TCR-T cells for clinical usage?

"As this is an initial phase 1 trial, the KK-LC-1 TCR-T cells are deemed to have a safety score of 1 due to the limited amount of clinical data supporting its efficacy and security." - Anonymous Online Contributor

Unverified Answer

Is there still capacity available for participants in this medical trial?

"Evidenced by the most recent update (dated September 26th 2022) on clinicaltrials.gov, this medical trial is seeking participants who meet its criteria. It was first posted to the site on that same date." - Anonymous Online Contributor

Unverified Answer

What is the enrollment maximum for this experiment?

"Yes, the evidence on clinicaltrials.gov affirms that this medical study is actively searching for participants. It was first uploaded on September 26th 2022 and updated recently with a goal of recruiting 42 patients from one site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.